Differences in caffeine 3-demethylation activity among inbred mouse strains:: A comparison of hepatic Cyp1a2 gene expression between two inbred strains

被引:11
作者
Casley, WL
Menzies, JA
Girard, M
Larocque, L
Mousseau, N
Whitehouse, LW
Moon, TW
机构
[1] Hlth Canada, Banting Res Ctr 2201C, Therapeut Prod Directorate, Bur Drug Res, Ottawa, ON K1A 0L2, Canada
[2] Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada
来源
FUNDAMENTAL AND APPLIED TOXICOLOGY | 1997年 / 40卷 / 02期
关键词
1,3,7-trimethylxanthine; caffeine; metabolism; mice; inbred strains; CYP1A2; genetics;
D O I
10.1006/faat.1997.2394
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The 3-demethylation of caffeine can be used as an index of cytochrome P450 CYP1A2 activity in vivo. We compared the plasma levels of caffeine and the 3-demethylated metabolite, 1,7-dimethylxanthine, in six common inbred strains (A/J, P/J, BALB/cJ, C3H/HeJ, AKR/J, and SWR/J) and one inbred strain (APN) derived in our laboratory from outbred Swiss-Webster mice on the basis of its relative susceptibility to acetaminophen-induced hepatotoxicity. We found significant variations between a number of the common strains, all of which produced significantly higher caffeine 3-demethylation indices than our APN strain. In three of the six common strains, there was a significant difference between males and females, with the females having consistently lower 1,7-xanthine/caffeine ratios. Hepatic Cyp1a2 expression was compared between APN and C3H/HeJ males, Microsomal methoxyresorufin O-demethylation, acetanilide 4-hydroxylation, and CYP1A2 immunoreactive protein levels were significantly higher in C3H/HeJ relative to APN mice, as were hepatic CYP1A2 mRNA levels, These results indicate the importance of strain and gender to the outcome of pharmacological or toxicological studies involving CYP1A2-mediated metabolism, as well as the suitability of the plasma 1,7-dimethylxanthine/caffeine ratio as a marker of CYP1A2 activity in the mouse. The striking differences observed between the APN and C3H/HeJ mice suggest that these strains may be suitable for a genetic analysis of the regulation of the basal expression of CYP1A2, a key enzyme in procarcinogen activation. (C) Society of Toxicology.
引用
收藏
页码:228 / 237
页数:10
相关论文
共 45 条
[1]  
AHOKAS JT, 1981, RES COMMUN SUBSTANCE, V2, P277
[2]   Mouse models of human disease .2. Recent progress and future directions [J].
Bedell, MA ;
Largaespada, DA ;
Jenkins, NA ;
Copeland, NG .
GENES & DEVELOPMENT, 1997, 11 (01) :11-43
[3]   GENBANK [J].
BENSON, DA ;
BOGUSKI, M ;
LIPMAN, DJ ;
OSTELL, J .
NUCLEIC ACIDS RESEARCH, 1994, 22 (17) :3441-3444
[4]   ACETAMINOPHEN HEPATOTOXICITY - CORRESPONDENCE OF SELECTIVE PROTEIN ARYLATION IN HUMAN AND MOUSE-LIVER INVITRO, IN CULTURE, AND INVIVO [J].
BIRGE, RB ;
BARTOLONE, JB ;
HART, SGE ;
NISHANIAN, EV ;
TYSON, CA ;
KHAIRALLAH, EA ;
COHEN, SD .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1990, 105 (03) :472-482
[5]   THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, AND PARACETAMOL AS PROBES [J].
BOCK, KW ;
SCHRENK, D ;
FORSTER, A ;
GRIESE, EU ;
MORIKE, K ;
BROCKMEIER, D ;
EICHELBAUM, M .
PHARMACOGENETICS, 1994, 4 (04) :209-218
[6]  
BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243
[7]   Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2 [J].
Buters, JTM ;
Tang, BK ;
Pineau, T ;
Gelboin, HV ;
Kimura, S ;
Gonzalez, FJ .
PHARMACOGENETICS, 1996, 6 (04) :291-296
[8]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[9]   CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine [J].
Carrillo, JA ;
Benitez, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (06) :605-608
[10]   Increased basal expression of hepatic Cyp1a1 and Cyp1a2 genes in inbred mice selected for susceptibility to acetaminophen-induced hepatotoxicity [J].
Casley, WL ;
Menzies, JA ;
Mousseau, N ;
Girard, M ;
Moon, TW ;
Whitehouse, LW .
PHARMACOGENETICS, 1997, 7 (04) :283-293